Tilting the AXIS towards therapeutic limits in renal cancer

The Lancet

Volumn 378, Issue 9807, 2011, Pages 1898-1900

  Bex, Axel ^a   Haanen, John ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; PLACEBO; SORAFENIB;

ASTHENIA; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; FATIGUE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; NAUSEA; NOTE; PRIORITY JOURNAL; VOMITING;

EID: 82755176287     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61655-3     Document Type: Note

References (11)

1. BI Rini, B Escudier, P Tomczak et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 2011 10.1016/S0140-6736(11)61613-9 published online Nov 4.
2. BI Rini, G Wilding, G Hudes et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4462 4468
3. O Rixe, RM Bukowski, MD Michaelson et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 2007 975 984 (Pubitemid 47629888)
4. YC Shih, CR Chien, Y Xu, IW Pan, GL Smith, TA Buchholz Economic burden of renal cell carcinoma in the US: part II - an updated analysis Pharmacoeconomics 29 2011 331 341
5. J Norum, C Nieder, M Kondo Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations J Chemother 22 2010 75 82
6. JJ Patard, G Pignot, B Escudier et al. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease Eur Urol 60 2011 684 690
7. RJ Motzer, B Escudier, S Oudard et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
8. C Coppin, C Kollmannsberger, L Le, F Porzsolt, TJ Wilt Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials BJU Int 2011 10.1111/j.1464-410X.2011.10629.x published online Sept 27.
9. M Hoyle, C Green, J Thompson-Coon et al. Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma Value Health 13 2010 55 60
10. M Pitt, L Crathorne, T Moxham, M Bond, C Hyde Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis Health Technol Assess 14 suppl 2 2010 41 46
11. BI Rini, DP Cohen, DR Lu et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 103 2011 763 773